BioCentury | Aug 1, 2018
Distillery Therapeutics

Pulmonary

...IPF patients. The generic metformin is marketed for Type II diabetes and polycystic ovary syndrome. Betagenon AB...
BioCentury | Apr 11, 2017
Distillery Therapeutics

Hepatic

...hepatic triglyceride levels. Next steps could include testing AMPK activators in other models of NAFLD. Betagenon AB...
BioCentury | Mar 8, 2017
Distillery Therapeutics

Musculoskeletal

...steps could include testing AMPK activators and mTORC1 inhibitors in other mouse models of DM1. Betagenon AB...
BioCentury | Sep 5, 2016
Clinical News

O304: Phase IIa started

...trial to evaluate 1,000 mg oral O304 once daily for 28 days in 66 patients. Betagenon AB...
BioCentury | Feb 16, 2012
Targets & Mechanisms

Still un-sirtuin

...Kyorin Pharmaceutical Co. Ltd. , which is marketed in Japan to treat asthma and stroke. Betagenon AB...
BioCentury | Nov 14, 2011
Clinical News

Betagenon preclinical data

...rats, the AMP-activated protein kinase (AMPK) activator stimulated the generation of active brown fat cells. Betagenon AB...
BioCentury | Apr 21, 2008
Finance

Ebb & Flow

...for milestones plus royalties (see B5). Antisoma (LSE:ASM) lost 0.3p to 27p last week after Betagenon...
BioCentury | Apr 21, 2008
Company News

Antisoma, Betagenon deal

...rights to develop and market undisclosed preclinical AMP-activated protein kinase (AMPK) activators to treat cancer. Betagenon...
...be eligible for undisclosed development and regulatory milestones, plus royalties. Antisoma plc (LSE:ASM), London, U.K. Betagenon AB...
BioCentury | Apr 15, 2008
Company News

Antisoma, Betagenon in cancer deal

...to develop and market its undisclosed preclinical AMP-activated protein kinase (AMPK) activators to treat cancer. Betagenon...
Items per page:
1 - 9 of 9
BioCentury | Aug 1, 2018
Distillery Therapeutics

Pulmonary

...IPF patients. The generic metformin is marketed for Type II diabetes and polycystic ovary syndrome. Betagenon AB...
BioCentury | Apr 11, 2017
Distillery Therapeutics

Hepatic

...hepatic triglyceride levels. Next steps could include testing AMPK activators in other models of NAFLD. Betagenon AB...
BioCentury | Mar 8, 2017
Distillery Therapeutics

Musculoskeletal

...steps could include testing AMPK activators and mTORC1 inhibitors in other mouse models of DM1. Betagenon AB...
BioCentury | Sep 5, 2016
Clinical News

O304: Phase IIa started

...trial to evaluate 1,000 mg oral O304 once daily for 28 days in 66 patients. Betagenon AB...
BioCentury | Feb 16, 2012
Targets & Mechanisms

Still un-sirtuin

...Kyorin Pharmaceutical Co. Ltd. , which is marketed in Japan to treat asthma and stroke. Betagenon AB...
BioCentury | Nov 14, 2011
Clinical News

Betagenon preclinical data

...rats, the AMP-activated protein kinase (AMPK) activator stimulated the generation of active brown fat cells. Betagenon AB...
BioCentury | Apr 21, 2008
Finance

Ebb & Flow

...for milestones plus royalties (see B5). Antisoma (LSE:ASM) lost 0.3p to 27p last week after Betagenon...
BioCentury | Apr 21, 2008
Company News

Antisoma, Betagenon deal

...rights to develop and market undisclosed preclinical AMP-activated protein kinase (AMPK) activators to treat cancer. Betagenon...
...be eligible for undisclosed development and regulatory milestones, plus royalties. Antisoma plc (LSE:ASM), London, U.K. Betagenon AB...
BioCentury | Apr 15, 2008
Company News

Antisoma, Betagenon in cancer deal

...to develop and market its undisclosed preclinical AMP-activated protein kinase (AMPK) activators to treat cancer. Betagenon...
Items per page:
1 - 9 of 9